



January 2023

Delivered by Corporate Media Relations

Service Lines

Preventing Cervical Cancer: An Expert Answers Your Questions



Jan 02 | **Online Publication** | Cara Murez | **Reach: 369,364** | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Health Day - Cervical cancer is preventable, but people often feel uncomfortable talking about it because of its link to the sexually transmitted human papillomavirus. Don't be embarrassed, a cancer expert advises. Not only does your doctor want to help you, but the virus is incredibly common, affecting most American adults, according to Dr. James Aikins Jr., chief of gynecologic oncology at Rutgers Cancer Institute of New Jersey, in New Brunswick. "Although abnormal Pap results can seem scary, abnormal results don't necessarily mean you have cervical cancer," Aikins said in a Rutgers news release. [Read More](#)

Also syndicated in:

US News & World Report, Drugs.com, STLtoday.com, Tulsa World, Messenger-Inquirer, The Wyoming Tribune-Eagle, Hickory Daily Record, The Watauga Democrat, Lowell General Hospital, FOX 28 News and 115 [More](#)

Syndicated Reach: TM - 70,029,067

Novel Regimen Significantly Lowers GVHD Risk After Reduced-intensity Allogeneic HSCT

Jan 03 | **Online Publication** | **Reach: 1,061,170** | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Healio - A regimen containing post-transplant cyclophosphamide significantly lowered graft-versus-host disease risk among adults who underwent reduced-intensity allogeneic hematopoietic stem cell transplant, study results showed. Data from the randomized, phase 3 BMT CTN 1703 study, presented at ASH Annual Meeting and Exposition, revealed those who received the GVHD prophylaxis regimen after transplantation with closely matched donor grafts had a twofold reduction in severe acute and chronic GVHD risk compared

with a control group of patients who received standard therapy with tacrolimus and methotrexate, Perspective from Ira Braunschweig, MD, Rutgers Cancer Institute of New Jersey, RWJBarnabas Health Oncology Service Line, Robert Wood Johnson University Hospital.

[Read More](#)

Study Uncovers Triple Immunotherapy Combination As Potential Treatment For Pancreatic Cancer

Jan 03 | **Online Publication** | **Reach: N/A** | **Sentiment : Positive**

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Journal Break - Pancreatic ductal adenocarcinoma is a highly lethal malignancy with a poor prognosis and limited treatment options. Researchers at the Rutgers Cancer Institute in New Jersey, the state's premier cancer program and the only Comprehensive Cancer Center designated by the National Cancer Institute, along with RWJBarnabas Health, in collaboration with researchers at the Anderson Cancer Center, MD, have discovered a novel triple combination immunotherapy, targeting checkpoints on both T cells and myeloid suppressor cells, which significantly improved the antitumor response by reprogramming the tumor microenvironment in preclinical PDAC models. Pratik Gulhati, MD, MD, a medical scientist in the gastrointestinal oncology program at the Rutgers Cancer Institute and an associate professor of medicine at the Robert Wood Johnson School of Medicine at Rutgers, is the lead author of the paper and shares more details on the results published in Nature Cancer. "PDAC is one of the leading causes of cancer death in the United States and is considered "non-immunogenic", meaning that it does not respond to commonly used anti-PD-1 and anti-CTLA-4 immune checkpoint therapies. This is partly due to immunosuppressive conditions in the tumor microenvironment, but the mechanisms underlying this resistance are not well understood." Pratik Gulhati said. [Read More](#)

What's The Connection Between HPV And Cervical Cancer?



Jan 03 | **Online Publication** | Reach: 10,314,250 | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

New Brunswick Patch - Cervical cancer is one of the most preventable cancers, yet more than 14,000 women in the U.S. will be diagnosed with the disease this year, according to the American Cancer Society. James K. Aikins, Jr., MD, FACOG, FACS, chief of Gynecologic Oncology at Rutgers Cancer Institute of New Jersey and associate professor of Obstetrics, Gynecology and Reproductive Sciences at Rutgers Robert Wood Johnson Medical School, answers questions about cervical cancer and HPV that you might be embarrassed to ask. "Cervical cancer is almost always caused by HPV, which nearly every sexually active person will be exposed to in their lifetime. People with healthy immune systems are able to clear the virus within one to two years, but when high-risk strains infect

specific cells of the cervix it can lead to abnormal cell growth and precancerous changes. Over time and with persistent infection, this can lead to cervical cancer." James K. Aikins said. [Read More](#)

Findings In Leukemia Reported From Rutgers University - The State University Of New Jersey

Jan 03 | **Online Publication** | **Reach:** N/A | **Sentiment :** Positive

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

NewsRx Hematology Daily - According to news reporting originating in New Brunswick, New Jersey, by NewsRx journalists, research stated, "Graft-versus-host disease remains a major complication after allogeneic hematopoietic stem cell transplantation, a widely used therapy for hematologic malignancies and blood disorders. Here, we report an unexpected role of cytokine leukemia inhibitory factor in protecting against GVHD development." Funders for this research include NIH National Cancer Institute, United States Department of Defense, New Jersey Commission on Cancer Research, NIH National Cancer Institute, National Institutes of Health - USA, Flow Cytometry/Cell Sorting shared resource of Rutgers Cancer Institute of New Jersey. Our news correspondents report that additional information may be obtained by contacting Zhaohui Feng, Rutgers University - The State University of New Jersey, Rutgers University Cancer Institute of New Jersey, Dept. of Radiation Oncology, New Brunswick, NJ, United States. [Read More](#)

Eline Continues To Inspire Years Later

Jan 03 | **Online Publication** | **Reach:** 6,021,038 | **Sentiment :** Positive

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

NHL.com - In November 2019, 10-year-old Grace Eline was honored by the Devils during the organization's Hockey Fights Cancer night. Eline had recently finished treatment for a germ cell brain tumor and became an inspiration for the Devils players, coaches, and greater community. "Grace Eline is such an amazing young woman," said Justin Edelman, SVP of Corporate Partnerships at RWJBarnabas Health." In addition to spreading holiday cheer and decorating her former treatment center, Eline had the opportunity to reunite with Hughes and show several Devils players around the Valerie Center at Newark Beth Israel Medical Center. "To come here and see some kids, if you put a smile on one kids face it helps. It was a good day coming here," Hughes said when the Devils visited Newark Beth Israel Medical Center in December. "We're all a part of this community ... a lot of people support us so we're just sending it back to the people that support us." [Read More](#)

Rutgers Cancer Institute of New Jersey: Study Uncovers Triple Immunotherapy Combination As Potential Treatment for Pancreatic Cancer

Jan 04 | **NewsWire** | **Reach:** N/A | **Sentiment :** Positive

Share article : [!\[\]\(eafc244b53721dd1ec133f0772f70fc7_img.jpg\)](#) | [!\[\]\(cb741e910ae1fce3b15fcd4605753ff5_img.jpg\)](#) | [!\[\]\(7db78e01f48713b9a2242a4e52c8494a_img.jpg\)](#) | [!\[\]\(fac5b4ae95a83ca5438f440b384c5905_img.jpg\)](#)

Targeted News Service - Researchers from Rutgers Cancer Institute of New Jersey, the state's leading cancer program and only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas Health, in collaboration with investigators from MD Anderson Cancer Center, discovered a novel triple immunotherapy combination, targeting checkpoints on both T cells and myeloid suppressor cells, that dramatically improved anti-tumor responses by reprogramming the tumor microenvironment in preclinical models of PDAC. Prateek Gulhati, MD, PhD, physician-scientist in the

Gastrointestinal Oncology Program at Rutgers Cancer Institute and assistant professor of medicine at Rutgers Robert Wood Johnson Medical School is the lead author of the work and shares more about the findings published in Nature Cancer. "PDAC is one of the leading causes of cancer death in the United States and is considered to be "non-immunogenic," which means it is unresponsive to commonly used anti-PD-1 and anti-CTLA-4 immune checkpoint therapy," said Prateek Gulhati. [Read More](#)

Pancreatic Cyst Surveillance Program at Cooperman Barnabas Medical Center



Jan 05 | **Broadcast** | **Reach:** 1,928,957 | **Sentiment :** Positive

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

WCBS-NY (CBS) - New York, NY - Cooperman Barnabas Medical Center's Pancreatic Cyst Surveillance Program, a new health research program, is on a mission to find clues in time to save lives. "We were absolutely thrilled to be the first in the region and one of the first in the country to onboard artificial intelligence for pancreatic cyst patients," said Dr. Russell C. Langan. "We know the cyst is the precursor lesion, so it's the perfect model to try to understand how do these cancers

develop," said Dr. Brett Ecker. The staff at Cooperman Barnabas Medical Center is working with the Rutgers Cancer Institute of New Jersey and software developer Eon Health. [Read More](#)

Also syndicated in:

WIAT, WTVY, WHNT, WKRG, WAKA, KYES, KXDF, KTNL, KPHO, KOLD and 201 More

Cooperman Barnabas Medical Center Using High-Tech Science To Lower Risk of Developing Pancreatic Cancer

Jan 05 | **Online Publication** | John Elliott | **Reach: 12,905,208** | Sentiment : **Positive**

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

CBS News - Cooperman Barnabas Medical Center's Pancreatic Cyst Surveillance Program, a new health research program, is on a mission to find clues in time to save lives. It's a cutting-edge combination of high-tech medical science and good old-fashioned medical sleuthing, said CBS2's John Elliott, who is in the program. "We were absolutely thrilled to be the first in the region and one of the first in the country to onboard artificial intelligence for pancreatic cyst patients," said Dr. Russell C. Langan. "We know the cyst is the precursor lesion, so it's the perfect model to try to understand how do these cancers develop," said Dr. Brett Ecker. The staff at Cooperman Barnabas Medical Center is working with the Rutgers Cancer Institute of New Jersey and software developer Eon Health. [Read More](#)

Also syndicated in:

NewsBreak, Head Topics, The New York Folk and Newyork Reporter

Syndicated Reach: TM - 6,715,775

St. Luke's To Partner With Rutgers Cancer Institute of New Jersey



Jan 09 | **Online Publication** | Josh Popichak | **Reach: 9,580** | Sentiment : **Positive**

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Saucon Source - St. Luke's University Health Network will expand its participation in clinical trials for cancer research through an innovative partnership with Rutgers Cancer Institute of New Jersey, the only National Cancer Institute-designated Comprehensive Cancer Center in New Jersey, together with RWJBarnabas Health. "We are excited to partner with St. Luke's to bring our innovative clinical trials to their patients and the communities they serve," said Steven K. Libutti, MD, Director of Rutgers Cancer Institute of New Jersey and Senior Vice President of Oncology Services, RWJBarnabas Health. "Cutting-edge cancer care from New Jersey's only NCI-designated Comprehensive Cancer Center transcends state borders." Rutgers Cancer Institute physician-scientists are major contributors and leaders in the development and execution of clinical trials from the National Cancer Institute and international cooperative groups. Their more than 230 faculty members collaborate with industry and other academic centers to conduct basic, clinical and population research for both adult and pediatric cancer patients. [Read More](#)

Prostate Cancer Consensus Conference Offers Guide to Clinical Dilemmas



Jan 10 | **Online Publication**| John Schieszer | **Reach: 65,824** |
Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Renal & Urology News - Clinicians may now have a better idea of how best to treat men with intermediate- and high-risk and locally advanced prostate cancer. “As a clinician, I found the paper useful as the survey questions represent scenarios that patients and physicians face every day,” said Saum Ghodoussipour, MD, a urologic oncologist who is an assistant professor of surgery at Rutgers Robert Wood Johnson Medical School and Director of the Bladder and Urothelial Cancer Program at Rutgers Cancer Institute of New Jersey in New Brunswick. [Read More](#)

RWJUH/Somerset Surgeons Perform New Sensation-Preserving Nipple-Sparing Mastectomy



Jan 10 | **Online Publication** | Reach: 1,493,932 | Sentiment : **Positive**

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

TAPinto Hillsborough - A team of physicians at Robert Wood Johnson University Hospital Somerset's Steeplechase Cancer Center, an RWJBarnabas Health facility, are performing a new mastectomy procedure that can significantly improve outcomes, minimize postoperative discomfort and enhance quality of life for their patients. Dr. Deborah Lue, board-certified breast surgeon, medical director of breast cancer services at the Steeplechase Cancer Center at RWJUH Somerset and member of the RWJBH Medical Group, and Dr. Colin Failey, board-certified plastic surgeon at Steeplechase Cancer Center, have recently completed several of the sensation-preserving nipple-sparing mastectomy procedures. "With more people surviving breast cancer today, it is necessary to look at long term quality of life for our patients," said Dr. Lue. "While the surgery is appropriate for most patients requiring a mastectomy, it is especially helpful for those who are undergoing a nipple-sparing mastectomy as it helps to maintain as

natural of a look and feel as possible after their recovery,” added Dr. Failey. “Thanks to the collaborative efforts between Drs. Lue and Failey, New Jersey patients facing a breast cancer diagnosis are able to opt for a groundbreaking procedure that has benefits beyond those of a traditional mastectomy,” said Kathleen Toomey, MD, medical director of the Steeplechase Cancer Center. [Read More](#)

Also syndicated in:

[Insider NJ](#)

Syndicated Reach: TM - 167,087

QSAM Biosciences Provides 2022 Update and 2023 Milestones to Shareholders

Jan 10 | **Organization** | [Reach: 360,694](#) | Sentiment : [Positive](#)

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

GuruFocus - Established two clinical trial sites, including Rutgers Cancer Institute of New Jersey, part of Rutgers Health and New Jersey’s only National Cancer Institute– designated Comprehensive Cancer Center, an elite recognition that is granted competitively to institutions based on their scientific leadership, resources, and outstanding track record of research discoveries and ability to translate these discoveries to benefit cancer patients. [Read More](#)

Also syndicated in:

[Yahoo! Finance](#), [Benzinga](#), [WPRI](#), [BioSpace](#), [FOX4](#), [FOX 31 News KDVR](#), [KHON 2](#), [Rochesterfirst.com](#), [MarketScreener.com](#), [The Associated Press](#) and 1 More

Syndicated Reach: TM - 69,633,733

70 Oncology Leaders on the Move in 2022

Jan 11 | **Online Publication** | [Mariah Taylor](#) | [Reach: 590,272](#) | Sentiment : [Positive](#)

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Becker's Hospital Review - Here are 70 oncology leaders who started new roles in 2022: New Brunswick, N.J.-based Rutgers Cancer Institute of New Jersey and RWJBarnabas Health named Matthew Matasar, MD, MS, as chief of blood disorders. Rutgers Cancer Institute of New Jersey named Sanjay Goel, MD, director of its investigational therapeutics program. [Read More](#)

HoLISTIC Consortium Develops Reliable Predictive Model for 5-Year Survival in Classic Hodgkin Lymphoma

Jan 11 | **Online Publication** | Brandon May | **Reach: 24,478** | Sentiment : **Positive**

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

ASO Daily News - Building on the International Prognostic Score, the goal of HoLISTIC was to create a multivariable prediction model capable of predicting PFS and OS by 5 years in adult patients with newly diagnosed, advanced stage cHL in the modern era. Despite the advantages of the original IPS, the scoring system has required critical updates in recent years, according to study author Andrew M. Evens, DO, MBA, MSc, of the Rutgers Robert Wood Johnson Medical School. “First, management strategies and outcomes have improved in cHL over the past 20 years,” Dr. Evens said, “[and] the IPS was largely developed on data from the 1980s in an era that included heavier reliance on alkylator therapy with/without total nodal irradiation.” [Read More](#)

Oncology Researcher To Join Rutgers Global Health Institute



Jan 12 | **Online Publication** | Reach: 100,205 | Sentiment : **Positive**

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Mirage News - Wilfred Ngwa, a global oncology researcher and medical physics expert who is developing technologies that integrate with radiation therapy to reduce cancer treatment times and costs, will join Rutgers Global Health Institute. Ngwa, who will become a Rutgers Presidential Faculty Scholar and a professor of global health at the institute in January, also will be appointed as a professor in the Department of Radiation Oncology at the Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School. “Expanding our multicenter clinical trials to additional U.S. and African institutions will be a focus of my research at Rutgers. Implementation research also will be a priority, so that we can turn knowledge into real-world actions that will improve health care delivery and global health,” Ngwa said. [Read More](#)

The Holistic Approach to Cancer Treatment

Jan 12 | **Online Publication** | Angela McCabe | Reach: 17,485 | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

New Jersey Business Magazine - The statistics on cancer are sobering. One in three men and one in two women will be diagnosed with cancer in their lifetime, according to the American Cancer Society. We know that a cancer diagnosis is life-changing for patients and their families. We also know that cancer doesn’t travel well, and patients ideally shouldn’t have to travel to multiple locations to receive the best care possible. But what does world-class cancer treatment look like? One thing is for certain. It’s about more than just medicine. Author includes Angela McCabe, MSW, LCSW, OSW-C is the director of patient and family services for oncology at Cooperman Barnabas Medical Center. [Read More](#)

Dr. George on the Risk of Cardiotoxicity With Adjuvant T-DM1 Plus Radiotherapy in HER2+ Breast Cancer


Jan 12 | **Online Publication** | Mridula George | **Reach: 121,472** |
Sentiment : Neutral

Share article : [!\[\]\(7377a3302f3d0fb3a834bf90f4594228_img.jpg\)](#) | [!\[\]\(280d20eb30edda888ea49b11139a3be7_img.jpg\)](#) | [!\[\]\(b5f97e7054ee78fe5f61d4f0345214fd_img.jpg\)](#) | [!\[\]\(e998c40a3119fe2e6fcad89de1fdcd94_img.jpg\)](#)

OncLive - Mridula George, MD, medical oncologist, Stacy Goldstein Breast Cancer Center, Rutgers Cancer Institute of New Jersey, assistant professor of medicine, Rutgers Robert Wood Johnson Medical School, discusses the evaluation of cardiotoxicity associated with adjuvant ado-trastuzumab emtansine (T-DM1; Kadcyla) with concurrent radiotherapy in patients with HER2-positive breast cancer. Adjuvant T-DM1 is the current standard of care for patients with residual breast cancer after neoadjuvant HER2-targeted therapy. Additionally, patients at a high risk of recurrence are routinely offered adjuvant radiation. Because T-DM1 is associated with a risk of cardiotoxicity, defined as a decline in left ventricular ejection fraction, investigators conducted an institutional review of cardiotoxicity experienced by patients with stage I to III HER2-positive breast cancer treated with adjuvant T-DM1 and concurrent radiation, George says.

[Read More](#)

Investments in Infrastructure, Education and Quality of Life Continue in Middlesex County



Jan 12 | **Online Publication**| Kathy Chang | **Reach: 42,359** | Sentiment
: **Positive**

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Centraljersey.com - The new Jack and Sheryl Morris Cancer Center is a state-of-the-art, freestanding cancer hospital featuring outpatient and inpatient capacity coupled with research laboratories, retail space and ancillary services devoted to patient wellness and is a first of its kind in New Jersey, according to Robert Wood Johnson Barnabas Health. [Read More](#)

RWJUH Somerset Surgeons Perform Sensation-Preserving Nipple-Sparing Mastectomy

Jan 12 | **NewsWire** | **Reach:** N/A | **Sentiment :** Positive

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Targeted News Service - A team of physicians at Robert Wood Johnson University Hospital Somerset's Steeplechase Cancer Center, an RWJBarnabas Health facility, are performing a mastectomy procedure that can significantly improve outcomes, minimize postoperative discomfort and enhance quality of life for their patients. Dr. Deborah Lue, board-certified breast surgeon, medical director of breast cancer services at the Steeplechase Cancer Center at RWJUH Somerset and member of the RWJBH Medical Group, and Dr. Colin Failey, board-certified plastic surgeon at Steeplechase Cancer Center, have recently completed several of the sensation-preserving nipple-sparing mastectomy procedures. The pair are one of the few of teams across the country, including colleagues across RWJBarnabas Health, who work to preserve the natural chest wall sensory nerves during a nipple-sparing mastectomy. "With more people surviving breast cancer today, it is necessary to look at long term quality of life for our patients," said Dr. Lue. "While the surgery is appropriate for most patients requiring a mastectomy, it is especially helpful for those who are undergoing a nipple-sparing mastectomy as it helps to maintain as

natural of a look and feel as possible after their recovery," added Dr. Failey. [Read More](#)

Oncology Researcher To Join Rutgers Global Health Institute

Jan 14 | **NewsWire** | **Reach:** N/A | **Sentiment :** Positive

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Targeted News Service - Wilfred Ngwa, a global oncology researcher and medical physics expert who is developing technologies that integrate with radiation therapy to reduce cancer treatment times and costs, will join Rutgers Global Health Institute. Ngwa, who will become a Rutgers Presidential Faculty Scholar and a professor of global health at the institute in January, also will be appointed as a professor in the Department of Radiation Oncology at the Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School. "Expanding our multicenter clinical trials to additional U.S. and African institutions will be a focus of my research at Rutgers. Implementation research also will be a priority, so that we can turn knowledge into real-world actions that will improve health care delivery and global health," Ngwa said. [Read More](#)

Approval of Mosunetuzumab Becomes 'Critically Important' First-Line Treatment Option in R/R Follicular Lymphoma, Expert Says

Jan 15 | **Online Publication** | Matthew J. Matasar | **Reach:** 91,460 | **Sentiment :** Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Cancernetwork.com - Results from the phase 2 GO29781 trial (NCT02500407) helped lead to the FDA approval of mosunetuxumab-

axgb (Lunsumio) for patients with relapsed/refractory follicular lymphoma, according to Matthew Matasar, MD. Matasar, an investigator of the study, chief of the Division of Blood Disorders at Rutgers Cancer Institute, and professor at Rutgers Robert Wood Johnson Medical School spoke with CancerNetwork regarding the trial's updated results that were presented at the 2022 American Society of Hematology Annual Meeting. Of note, the agent yielded an objective response rate of 78% and a complete response of 60%. Moreover the 24-month DOR rate was 53% (95% CI, 38%-68%), and the 24-month duration of CR rate was 63% (95% CI, 38%-88%). [Read More](#)

RSNA 2022 Theme in Action: Empowering Patients and Partners in Care



Jan 16 | **Online Publication** | Christine Book | **Reach: 45,727** |
Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Imaging Technology News - Of the hundreds of educational sessions, scientific findings presented and conversations, we challenged ourselves to find the top quotes that underscored the theme of this year's meeting. With more to come in ongoing coverage, and in the spirit of "In Case You Missed It," here, then, a handful worthy of sharing. "The major challenge is determining how we demonstrate imaging's value to the greater healthcare community. Patient reported outcomes are understudied and underreported, offering metrics which have been tested and validated the research is an endeavor worthy of our support. Armed with this knowledge, we can expand our own lens to see the bigger picture of our patients' medical journey. Imaging's true value to the patient quality of life, comfort, peace of mind, certainty, hope, trust lies below the surface for us to explore together." —Bruce G. Haffty, MD, MS, RSNA Immediate Past President; Chair of Radiation Oncology, Associate Vice Chancellor for Cancer Programs, Rutgers Cancer Institute of New Jersey; System Director of Radiation Oncology, RWJBarnabas Health. [Read More](#)

Oncology Researcher Joins Rutgers Global Health Institute

Jan 17 | **Online Publication** | **Reach: 167,087** | Sentiment : **Positive**

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Insider NJ - Wilfred Ngwa, named a Rutgers Presidential Faculty Scholar and a professor of global health, advises the Biden Administration's Cancer Cabinet. Wilfred Ngwa, a global oncology researcher and medical physics expert who is developing technologies that integrate with radiation therapy to reduce cancer treatment times and costs, has joined Rutgers Global Health Institute. Ngwa, who is a Rutgers Presidential Faculty Scholar and a professor of global health

at the institute, also holds an appointment as a professor in the Department of Radiation Oncology at the Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School. [Read More](#)

Also syndicated in:

[New Jersey News Network](#)

Mosunetuzumab Appears To Reduce Unmet Needs Associated With CAR T-Cell Therapy for R/R Follicular Lymphoma

Jan 17 | **Online Publication** | Matthew J. Matasar | **Reach: 91,460** | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Cancernetwork.com - The recent approval of mosunetuzumab-axgb (Lunsumio) for patients with relapsed/refractory follicular lymphoma could work to resolve a handful of the unmet needs left by CAR T-cell therapy, such as cost, access, and tolerability, without sacrificing efficacy, according to Matthew Matasar, MD, in an interview with CancerNetwork. The FDA approval for mosunetuzumab is based on data from the phase 2 GO29781 trial (NCT02500407). Matasar, chief of the Division of Blood Disorders at Rutgers Cancer Institute, professor at Rutgers Robert Wood Johnson Medical School, and an investigator on the study, went into detail about the agent's toxicity profile. Grade 3 or higher treatment-related adverse effects were observed in 51% of patients, with the most common being neutropenia and hypophosphatemia. [Read More](#)

NAPBC Recognizes Accredited Sites

Jan 17 | **Organization** | **Reach: N/A** | Sentiment : **Positive**

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

American College of Surgeons - The ACS NAPBC recognizes the following breast sites for demonstrating their commitment to providing high-quality, patient-centered cancer care to patients and the community by recently earning NAPBC reaccreditation: UCHHealth Highlands Ranch Hospital, Highlands Ranch, CO; Curtis and Elizabeth Anderson Cancer Institute, Savannah, GA; Hackensack University Medical Center, Hackensack, NJ; The Cancer Hospital at RWJUH Breast Care Connection, New Brunswick, NJ; The Breast Health Center at Kent, Warwick, RI; HCA Houston Healthcare Clearlake, Webster, TX. [Read More](#)

A Comprehensive Guide to Common Women's Health Issues

Jan 18 | **Online Publication** | Nancy Parello | **Reach: 16,999** |
Sentiment : Neutral

Share article : [**f**](#) | [!\[\]\(f152152632903f782d05f2953c43b347_img.jpg\)](#) | [**in**](#) | [!\[\]\(9190417dc825cc417a79995d1514ca2f_img.jpg\)](#)

Jersey's Best - The most common diseases among women are heart disease, cancer, respiratory disease, strokes and Alzheimer's disease, according to Dr. Robert A. Graebe, chairman and program director of the Department of Obstetrics and Gynecology at Monmouth Medical Center, an RWJBarnabas Health facility. "We commonly think of heart disease as a man's disease, but both men and women are probably equally afflicted. It also causes more morbidity and mortality in women than men," said Graebe, who is also a member of the combined

medical group of RWJBarnabas Health and Rutgers Health. [Read More](#)

Examining Ongoing Studies of Mosunetuzumab for R/R Follicular Lymphoma and Addressing Accessibility

Jan 19 | **Online Publication** | Matthew J. Matasar | **Reach: 91,460** | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Cancernetwork.com - Discussing how the agent will be assessed in different lines and in other B-cell malignancies, Matasar, chief of the Division of Blood Disorders at Rutgers Cancer Institute and professor at Rutgers Robert Wood Johnson Medical School, also discussed the need for this treatment to be available not only at academic centers, but also in greater community setting. "There's a lot of work ongoing, with mosunetuzumab specifically and with other bispecific antibodies as well. Most of the work being done in multiple areas: Within follicular lymphoma, it's being tested in combination with other agents, such as IMiDs and other monoclonal antibodies" said Matthew Matasar. [Read More](#)

Nab-Paclitaxel and Biliary Tract Cancer OS

Jan 20 | **Organization** | Rachna Shroff | **Reach: 6,588** | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

SWOG - These results are from the phase 3 S1815 trial conducted by the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute. The findings will be delivered in an oral presentation at the 2023 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology on January 20. In addition to Shroff and Philip, authors on the abstract include E.

Gabriela Chiorean, MD, of Fred Hutchinson Cancer Center and University of Washington School of Medicine; and Howard S. Hochster, MD, of Rutgers Cancer Institute. [Read More](#)

Also syndicated in:

EurekAlert!

Syndicated Reach: TM - 552,832

Dysregulation of the PRUNE2/PCA3 Genetic Axis in Human Prostate Cancer: From Experimental Discovery to Validation in Two Independent Patient Cohorts

Jan 23 | **Online Publication** | Reach: 56,168 | Sentiment : **Positive**

Share article : [!\[\]\(77e670be72de63f664b9f3cf25895195_img.jpg\)](#) | [!\[\]\(558e4872bad868ea459af0bae7f9949a_img.jpg\)](#) | [!\[\]\(291c623f5e124111b8a2f95e488aba9f_img.jpg\)](#) | [!\[\]\(3c11b8426f06077789132f89050a6c63_img.jpg\)](#)

UroToday - We have previously shown that the long non-coding RNA prostate cancer associated 3 functions as a trans-dominant negative oncogene by targeting the previously unrecognized prostate cancer suppressor gene PRUNE2, thereby forming a functional unit within a unique allelic locus in human cells. Here we investigated the PCA3/PRUNE2 regulatory axis from early to late genetic events during human prostate cancer progression. This work has been funded in part by the NCI Cancer Center Support Grants to the University of New Mexico Comprehensive Cancer Center and the Rutgers Cancer Institute of New Jersey. [Read More](#)

Smoking at Breast Cancer Diagnosis Linked to Higher Mortality Risk Among Black Women

Jan 24 | **Online Publication** | Jennifer Southall | **Reach: 1,424,496** |
Sentiment : Neutral

Share article : [!\[\]\(ec4bf86fbc20b4c99c0e88e3c82e29ee_img.jpg\)](#) | [!\[\]\(9a2d790df87f713fcf934753fd17af0c_img.jpg\)](#) | [!\[\]\(e9044af931fa8fbfdbbf8b9c54586345_img.jpg\)](#) | [!\[\]\(24bb8d4a10e927b537f37f89881ea200_img.jpg\)](#)

Healio - Black women who smoked at the time of breast cancer diagnosis had a 52% increased risk for all-cause mortality compared with Black women who never smoked, according to study results published in JAMA Network Open. Limited data exist on how lifestyle factors are associated with breast cancer prognosis among Black women because most of the evidence is based on studies of white breast cancer survivors, Nur Zeinomar, PhD, MPH, associate member of the cancer prevention and control program at Rutgers Cancer Institute, told Healio. “Having a healthy lifestyle that includes limited

alcohol consumption and not smoking has been associated with improved survival following a breast cancer diagnosis,” Zeinomar said.

[Read More](#)

Related Stories:

Investigators Explore Impact of Cigarette Smoking and Alcohol Consumption on Black Breast Cancer Survivors

Jan 24 | **Online Publication** | Medical Xpress | **Reach: 878,278** |
Sentiment : Neutral

Investigators Explore Impact of Cigarette Smoking and Alcohol Consumption on Black Breast Cancer Survivors

Jan 24 | **Online Publication** | **Reach: 878,278** | Sentiment : Neutral

Share article : [!\[\]\(41ede330716e633900ec1a60a7f07465_img.jpg\)](#) | [!\[\]\(99ae983cae298406fa49f5a7ce293404_img.jpg\)](#) | [!\[\]\(bf890dc17e5651792942b2b39a8e7ee0_img.jpg\)](#) | [!\[\]\(7dbfc7f5a53db34443a3cb348f7fada7_img.jpg\)](#)

Medical Xpress - Investigators from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas Health, found that a higher risk of mortality in Black breast cancer survivors is associated with a history of cigarette smoking along with regular alcohol consumption at the time of diagnosis. The work, led by Nur Zeinomar, Ph.D., MPH, associate member of the Cancer Prevention and Control Program at Rutgers Cancer Institute, along with senior author Elisa V. Bandera, MD, Ph.D. of Rutgers Cancer Institute, Rutgers School of Public Health and Rutgers Robert Wood Johnson

Medical School, is published in JAMA Network Open. "Our findings add to the evidence of the detrimental health impacts of smoking and underscore the need of tailored and targeted survivorship care for breast cancer survivors, particularly Black women and those with heavier levels of smoking," notes Dr. Zeinomar [Read More](#)

Also syndicated in:

[New Brunswick Patch](#)

Syndicated Reach: TM - 11,333,282

Robert Wood Johnson University Hospital's Breast Care Connection Granted Accredited Status From the American College of Surgeons

Jan 25 | **Online Publication** | **Reach: 1,382,047** | Sentiment : **Positive**

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

TAPinto Edison - The National Accreditation Program for Breast Centers, a quality program administered by the American College of Surgeons has granted accredited status to Robert Wood Johnson University Hospital's Breast Care Connection. RWJUH has held accredited status since 1999. RWJUH, an RWJBarnabas Health facility, together with Rutgers Cancer Institute of New Jersey, is the state's only National Cancer Institute-designated Comprehensive Cancer Center and leading cancer program. "Receiving re-accreditation from the NAPBC demonstrates the strong commitment of our robust team at Rutgers Cancer Institute of New Jersey in collaboration with RWJUH to providing the highest quality, personalized care to breast cancer patients in our community, through advanced treatments, research and clinical trials," says Deborah Toppmeyer, MD, Chief Medical Officer, Director, Stacy Goldstein Breast Cancer Center, Director, LIFE Center and Chief, Medical Oncology at Rutgers Cancer Institute. [Read More](#)

Syndicated Reach: TM - 1,382,047

Triple Immunotherapy Combo May Treat Pancreatic Cancer

Jan 25 | **Online Publication** | Reach: 151,297 | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Mirage News - Pancreatic ductal adenocarcinoma, a type of pancreatic cancer, is a highly lethal malignancy with poor prognosis and limited treatment options. Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas Health, in collaboration with investigators from MD Anderson Cancer Center, discovered a novel triple immunotherapy combination. Prateek Gulhati, a physician-scientist in the Gastrointestinal Oncology Program at Rutgers Cancer Institute and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School is the lead author of the work. [Read More](#)

Also syndicated in:

[States News Service](#)

Robert Wood Johnson University Hospital's Breast Care Connection Granted Accredited Status From American College of Surgeons

Jan 26 | **Online Publication** | Linda Lindner | Reach: 21,165 | Sentiment : **Positive**

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

ROI-NJ - The American College of Surgeons' National Accreditation Program for Breast Centers said it has granted accredited status to Robert Wood Johnson University Hospital's Breast Care Connection. RWJUH has held accredited status since 1999. RWJUH, an

RWJBarnabas Health facility, together with Rutgers Cancer Institute of New Jersey, is the state's only National Cancer Institute-designated Comprehensive Cancer Center and leading cancer program.

"Receiving reaccreditation from the NAPBC demonstrates the strong commitment of our robust team at Rutgers Cancer Institute of New Jersey in collaboration with RWJUH to providing the highest quality, personalized care to breast cancer patients in our community, through advanced treatments, research and clinical trials," Dr. Deborah Toppmeyer, chief medical officer, said. [Read More](#)

Trenton Asbestos Law Firm Highlights Symptoms of Mesothelioma

Jan 27 | **Online Publication** | **Reach: 5,000** | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Lifestyle - The Podcast Park - New Jersey has some of the most hazardous jobs in the world. It has some of the highest rates of asbestos exposure and mesothelioma. In 2018, 73 men and 40 women in New Jersey were diagnosed with mesothelioma, according to NJSHAD. If someone was exposed to asbestos in New Jersey, contact a New Jersey asbestos and mesothelioma lawyer immediately. Get local treatment for Asbestos Exposure and Mesothelioma: Cancer Center at RWJ Hamilton. Mesothelioma is a type of cancer that is caused by exposure to asbestos. It can develop in the thin layer of tissue covering many internal organs, known as the mesothelium. [Read More](#)

Perioperative Chemo Matches Multimodal TX for Locally Advanced Esophageal/GEJ Cancer

Jan 27 | **Online Publication** | Charles Bankhead | **Reach: 2,093,850** | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Medpage Today - Perioperative chemotherapy for locally advanced esophageal/gastroesophageal junction cancer led to outcomes similar to those achieved with more intensive multimodal therapy, according to a randomized trial reported here. Patients who receive chemoradiation in accordance with the CROSS trial can receive adjuvant nivolumab, which doubled disease-free survival in CheckMate 577, noted Salma Jabbour, MD, of Rutgers Cancer Institute of New Jersey in New Brunswick. The evidence shows that residual disease after surgery is associated with higher rates of local and distant failure and is an indication for adjuvant radiation. [Read More](#)

Adjuvant T-DM1 Plus Concurrent Radiation Not Associated With Increased Cardiotoxicity in HER2+ Breast Cancer

Jan 30 | **Online Publication** | Ryan Scott | **Reach: 117,114** | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

OncLive - Adjuvant ado-trastuzumab emtansine plus concurrent radiation therapy did not result in cardiotoxicities in patients with early-stage HER2-positive breast cancer, according to data from an retrospective institutional study presented in a poster at the 2022 San Antonio Breast Cancer Symposium. “Based on this small study, we have sufficient data to say that [adjuvant trastuzumab emtansine plus breast radiation] is safe. However, the sample size is a limitation of the study. A larger study looking at this question, specifically using more sensitive cardiac biomarkers, would give us more information,” lead study author Mridula George, MD, medical oncologist at the Stacy Goldstein Breast Cancer Center, Rutgers Cancer Institute of New Jersey, and an assistant professor of medicine at Rutgers Robert

Wood Johnson Medical School in New Brunswick, New Jersey, explained. [Read More](#)

Cancer Prevention Experts Provide Top Tips for Reducing Cancer Risk



Jan 30 | **Online Publication** | **Reach:** 11,333,282 | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

New Brunswick Patch - Many forms of cancer are preventable. Although risk factors such as age or genetics cannot be changed, other risk factors for cancer including healthy lifestyle choices are within your control. Elisa V. Bandera, MD, PhD and Carolyn J. Heckman, PhD, co-leaders of the Cancer Prevention and Control Research Program at Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute- Designated Comprehensive Cancer Center, together with RWJBarnabas Health, share their top tips for cancer prevention during National Cancer Prevention Month.

"Eating a well-balanced diet, regular physical activity and maintaining a healthy body weight have many health benefits. All three factors can reduce cancer risk and have been linked to better overall health and improved quality of life and prognosis after a cancer diagnosis." [Read More](#)

Also syndicated in:

[News-Medical.Net](#) and [Medical Xpress](#)

Syndicated Reach: TM - 4,791,191

Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications

Jan 30 | **Online Publication** | Saum Ghodoussipour | **Reach: 127,066** | Sentiment : **Positive**

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Physician's Weekly - Patients undergoing radical cystectomy frequently suffer from infectious complications, including urinary tract infections and surgical site infections leading to emergency department visits, hospital readmission, and added cost. To summarize the literature regarding perioperative antibiotic prophylaxis, ureteric stent usage, and prevalence of infectious complications after cystectomy. Contributor: Saum Ghodoussipour Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick. [Read More](#)

Cancer Survivors May Be at Risk for Heart Disease



Jan 30 | **Online Publication** | **Reach: 11,333,282** | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

New Brunswick Patch - While cancer treatments such as chemotherapy and radiation are critical to treating cancers, research shows that some of these treatments may impair heart function or cause long-term heart damage. These may include cardiac medications and procedures to better regulate the heart rhythm or pulse, monitoring the cardiac function of patients when they start chemotherapy or radiation therapy using a variety of imaging tests or recommending dietary changes and other lifestyle changes, if necessary, to help keep a patient's heart healthy during cancer treatment. The Cardio-Oncology Program at Rutgers Cancer Institute of New Jersey, the state's only NCI-designated Comprehensive Cancer Center in collaboration with RWJBarnabas Health, offers this type of specialized care at several of its locations across the state. Andrew M. Evens, DO, MBA, MSc, associate director for Clinical Services at Rutgers Cancer Institute of New Jersey and medical

director of the Oncology Service Line at RWJBarnabas Health, is a participating physician in the Cardio-Oncology Program at Rutgers Cancer Institute of New Jersey. [Read More](#)

Also syndicated in:

[News-Medical.Net](#)

Syndicated Reach: TM - 3,912,913

Spotlight on Rare Diseases: Gallbladder and Bile Duct Cancers

Jan 30 | **Online Publication** | [Reach: 11,333,282](#) | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

New Brunswick Patch - Bile duct and gallbladder cancers are uncommon, with an estimated 12,130 new cases diagnosed this year according to the American Cancer Society. Miral Sadaria Grandhi, MD, is director of hepatobiliary surgery at Rutgers Cancer Institute of New Jersey and associate professor of surgery at Rutgers Robert Wood Johnson Medical School. Learn more about the Liver Cancer and Bile Duct Cancer Program at the state's only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas. [Read More](#)

5 Systems Hiring Oncology Leaders

Jan 31 | **Online Publication** | Mariah Taylor | [Reach: 549,018](#) | Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

Becker's Hospital Review - Here are five systems hiring oncology leaders: Ohio State University Wexner Medical Center, based in Columbus, is seeking a director of its division of surgical oncology. Rutgers Cancer Institute of New Jersey, based in New Brunswick, is looking for a director of oncology services. [Read More](#)

The Future of Personalized Care in Oligometastatic Prostate Cancer



Jan 31 | **Online Publication** | Zachary Bessette | **Reach: 5,000** |
Sentiment : Neutral

Share article : [f](#) | [t](#) | [in](#) | [✉](#)

GU Oncology Now - "The two realms that we can probably benefit patients a lot are the two things that we've kind of talked about. One is continuing to integrate this more advanced imaging, things like PSMA, into patients with prostate cancer, and two, better understanding the genetics of these patients. And I think that's a lot of the work that's going to come out in the near future." Matthew Deek, MD, Department of Radiation Oncology, Rutgers Cancer Institute, New Brunswick, NJ, shares with us what research should be done to better personalize care for patients with oligometastatic prostate cancer. [Read More](#)

Recommended by Fullintel Analysts

You are currently subscribed as info@fullintel.com. For further assistance,
please contact Customer Service at support@fullintel.com

[Unsubscribe](#) | [Privacy Policy](#)

Copyright 2022 Fullintel, LLC. All Rights Reserved.

Powered by **Fullintel**